TP53 and breast cancer: The stapled α-helical peptide ATSP-7041, the first potent dual inhibitor of MDM2 and MDMX activities, achieved effective suppression of tumor growth through the activation of the p53 pathway in p53 wild-type cancer cell lines derived from osteosarcoma and breast cancer in vitro and in vivo [15].